Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe its the Trans-Atlantic call to Les.
He has never bashed CYRX to my knowledge.
He relentlessly bashes small biotechs, seemingly trying to force them into bankruptcy.
I think he is correct on Cryoport. He writes for the street.com.
I dislike his bashing of most small biotech companies.
Really dislike this guy, but for some reason he has taken a shine to Cryoport.....
H2R, I bet you can attest to my dislike, no?
@adamfeuerstein Jefferies out with CAR-T survey on $KITE's product. Have you looked at $CYRX? "Selling shovels to miners"
I found this interesting.
Federated...
Equity Ownership CYRX
Funds
Institutions
Name Ownership Trend
Previous 8 Qtrs Shares Change % Total
Shares Held % Total
Assets Date
Federated Equity Mgmt Co. Of Penn Premium 1,000,000 1,000,000 4.18 0.35 03/31/2017
Perkins Capital Management Inc Premium 410,606 356,061 1.72 1 03/31/2017
Vanguard Group Inc Premium 166,881 123,868 0.95 0 12/31/2016
Davidson D A & Co Premium 72,000 3,500 0.41 0.01 12/31/2016
Stifel Nicolaus Investment Advisors Premium 34,832 0 0.20 0 12/31/2016
FAF Advisors Inc Premium 12,684 3,154 0.07 0 12/31/2016
Wells Fargo Advisors, LLC Premium 7,298 -19,493 0.04 0 12/31/2016
Morgan Stanley Smith Barney LLC Premium 6,850 4,850 0.04 0 12/31/2016
Guggenheim Funds Investment Advisors LLC Premium 4,294 0 0.02 0.04 05/03/2017
BlackRock Fund Advisors Premium 2,880 0 0.02 0 12/31/2016
Total: Top 10 institutions Premium 1,718,325 1,471,940 7.65
http://investors.morningstar.com/ownership/shareholders-overview.html?t=CYRX
This might be of interest.
https://endpts.com/that-turnaround-on-new-fda-drug-approvals-were-right-on-schedule/
New Products
That turnaround on new FDA drug approvals? We’re right on schedule
by John Carroll
April 19, 2017 10:31 AM EDT
Updated: 11:30 AM
We were due for a pretty good year on new drug approvals from the FDA, and so far the agency and the industry have been performing on schedule.
Last year at this time the FDA had recorded just 7 new drug OKs on the way to a miserable 22 new drug approvals for 2016. In a number of cases the anemic rate of approvals was fed by temporary reversals based on manufacturing snafus, a condition still acutely felt at AstraZeneca, which just had its second rejection on ZS-9.
This year, a little more than a quarter into the year, we have 14 new drug approvals, including the recent green light for Neurocrine’s Ingrezza. The full list includes the questionable and controversial orphan drug approval of the steroid deflazacort for Duchenne muscular dystrophy, now owned by PTC Therapeutics. But it also includes some likely blockbusters, most notably Ocrevus from Roche and Dupixent from the cross-company team at Regeneron and Sanofi.
Most analysts were expecting a significantly better year in 2017 compared to 2016. New drug approvals rose at a fast clip in the previous few years, jumping to 45 in 2015 and triggering some buoyant expectations that the industry had turned the corner on a bleak period of scant product releases.
The question now is whether new approvals can get close to that 2015 number. RAPS counted the scheduled PDUFA deadlines and came up with 20, after you deduct the newly spurned baricitinib, which may hold back the expected bottom line. They all won’t make it to the market.
The jury is still out on that, but this year’s early crop of new products bodes well for the rest of 2017.
1 trulance plecanatide Synergy
2 parsabiv etelcalcetide Kai Pharma
3 emflaza deflazacort Marathon*
4 siliq brodalumab Valeant
5 xermelo telotristat ethyl Lexicon
6 kisqali ribociclib Novartis
7 xadago safinamide Newron
8 bavencio avelumab EMD Serono
9 symproic naldemedine Shionogi
10 zejula niraparib Tesaro
11 dupixent dupilumab Roche/Sanofi
12 ocrevus ocrelizumab Genentech
13 austedo deutetrabenazine Teva
14 ingrezza valbenazine Neurocrine
Did he give a price target and revenue estimate?
I have thought about a subscription. maybe time to bite the bullet?
If anyone has a subscription, maybe they can post a synopsis.
https://smithonstocks.com/comp/
Maybe they will do it at ASCO. That would do something to the share price!
It is if you are short.
These are the tactics of swing traders. You're gonna make millions when they are long, and the sky is falling when they sold it all and want to buy back lower. It is quite annoying to read all day long, though.
This was interesting also.....
https://finance.yahoo.com/news/kite-completes-submission-u-biologics-191500909.html
If there is any upside, this was done with 2 relatively large, stable New York firms. What we need from them is to get a recommendation out on Cryoport, that would stir up some interest, and we hopefully will not have to trade by appointment any longer. Also, there were no warrants associated with the offering. I am hopeful, fingers crossed that just maybe the money is needed for business expansion, as in more vessels. They keep telling us that we are getting all this business. I sure hope we are.
He certainly looks great considering all the chemo poison they put in him before he received DcVax Direct.
Thank you, Sojourner.
This is just a gut feeling, but if the lawsuit is finally cleared this Tuesday, we may start to see news flow.
I guesss even the "experts" like you are WRONG also.....
https://www.nwbio.com/clinical-trials/
I am also thinking they (the shorts)want a cloud overhanging the stock. The notes were pushed out to June basically, and the lawsuit may be over on Tuesday. Just a new way to cast fear, in another way and delay any new buying. Curious that some of the investors do not want their names known, hence the class C warrants.
I had also posted this about Jazz Pharmaceuticals. It is also very relevant to NWBO, because they, as you will read, were almost BK, and were wondering what to do. It shows that other companies have made it through tough times, so NWBO certainly can also.
It was originally posted by MD1225.
https://www.jazzpharma.com/wp-content/uploads/2015/10/Life-Science-Leader.pdf
It is kinda ironic because Jazz bought Celator.
Because this is a shelf registration filed on September 23, 2016.
The hold was lifted in 2017.
On September 23, 2016, we filed with the Securities and Exchange Commission, or SEC, a registration statement on Form S-3 (File No. 333-213777) utilizing a shelf registration process relating to the securities described in this prospectus supplement. Under this shelf registration process, we may, from time to time, sell up to $150 million in the aggregate of common stock, preferred stock, warrants, various series of debt securities, share purchase contracts, share purchase units, and warrants to purchase any of such securities, either individually or in units.
Continuing on your Celator theme, those with spare time should read the I-Hub Celator board. I did, it is still up and only 650 posts.
It reads a lot like the Northwest board. The price would go up to $2.50 and back down to $1.50. Loads of frustration, just like on NWBO.
Then this beauty was released just 2 weeks before the price exploded:
https://www.thestreetsweeper.org/undersurveillance/Celator_Pharmaceuticals__Eight_Key_Risks_Threaten_To_Chop_This_Stock
Same old drivel, they cherry picked patients, management was lining their pockets with huge salaries, right out of the playbook.
Keep the faith longs....
Beach,
If I remember correctly, and that is a stretch, I believe Alan Butler's tumor was inoperable, and the effects of direct made it operable. Does that ring a bell?
Wrong, again.
They can have 75% of the shares, there still have to have a vote!
They would short it back down under a dollar...
With all of this talk about a R/S, there is one thing you are all missing. They need a shareholder vote to authorize it.
They are lawyers. Silence until the papers are signed.
I also find the cash raise curious to the settlement.
Maybe cognate has to pay NWBO, and Nwbo had to pay Cognate
for past bills, so Cognate could pay them. This is purely wild speculation on my part.
This could be the reason....
https://www.technologyreview.com/s/603762/this-lab-in-a-box-could-make-gene-therapy-less-elitist/
Novartis will apply for permission to sell the treatment this year, but the company isn’t too happy with how the therapy is made. For its study, Novartis says that it air-shipped patients’ cells back and forth to a single cell-processing factory it owns in Morris Plains, New Jersey, with the help of Cryoport, a company specializing in shipping frozen cells. It’s logistically complex, labor-intensive, expensive, and potentially unpredictable, since no two people’s cells are the same. What’s more, Novartis isn’t certain how many patients it will actually be able to treat.
Could also be FDA approval of Kite.
Now that would help us immensely.
The way I remember it was when baldie interviewed butthead, DePhino was out of town. Newman was trying to put out the fires, and when DePhino came back, he had buttheads back, and all communication stopped. DePhino was all about the money and big pharma. Too bad he lost too much of MD Andersons money. And it seems in the process they lost being a player in the DcVax platform. Maybe Cramer the Clown will hire him to work with baldie.
Fidelity uses Knight Capital.
Can you take Buzdar with you?
Good Riddance!
http://www.modernhealthcare.com/article/20170308/NEWS/170309897
So, she is saying that 14% of the treatment arm did not receive DCvxL?
I may be an idiot, but should this not read that 14% of the placebo patients did not receive DCvax L. This would substantially change the end math?
There was not a vote for a reverse split!
TC,
They also filed to raise 20 million in late December.
https://eresearch.fidelity.com/eresearch/evaluate/news/basicNewsStory.jhtml?symbols=IMUC&storyid=201612280814MIDNIGHTUSEQUITY_A1344940&provider=MIDNIGHT&product=USEQUITY&sb=1
This is selling over 250% of the company.
Well, I found it.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On September 21, 2016, the Board of Directors of Cryoport, Inc. (the “Company”) adopted a resolution to change the Company’s fiscal year end from March 31 to December 31, effective immediately as of the date of the board resolution. Consequently, the Company will file an annual report on Form 10-K for the nine-month period ended December 31, 2016 to cover such transition period.
https://www.sec.gov/Archives/edgar/data/1124524/000114420416125093/v449307_8k.htm
They have changed their corporate calendar and their end of year is now Dec 31st. Used to be March 31st. So, now they have until March 31st to file their 10-K. I read this in one of the filings, but at the moment I am too lazy to find it.